Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javle

Showing results (221-230 of 343) with videos related to

Pageof 35
Sort By:
JCI Insight|December 7, 2023
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbonYan Zhu, Dengyong Zhang, Pooja Shukla, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional AnalysisSunyoung S Lee, Dong Hyun Seo, Taek Chung, et al.
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Pageof 35

Showing results (221-230 of 343) with videos related to

Sort By:
Pageof 35
JCI Insight|December 7, 2023
CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbonYan Zhu, Dengyong Zhang, Pooja Shukla, et al.
JAMA Oncology|April 19, 2019
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical TrialRachna T Shroff, Milind M Javle, Lianchun Xiao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2011
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progressionChristopher H Crane, Gauri R Varadhachary, John S Yordy, et al.
JAMA Surgery|July 16, 2020
Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
Annals of Surgery|January 3, 2020
Postoperative Chemotherapy Benefits Patients Who Received Preoperative Therapy and Pancreatectomy for Pancreatic AdenocarcinomaGiampaolo Perri, Laura Prakash, Wei Qiao, et al.
The Oncologist|March 26, 2025
A phase I/II trial of avelumab combinations with ivuxolimab, utomilumab, and radiation therapy in patients with advanced gastrointestinal malignanciesJibran Ahmed, Anne Knisely, Carlos Torrado, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2025
HER2-Positivity as a Prognostic Biomarker and Therapeutic Target in Advanced Biliary Tract Cancer: A Multi-Institutional AnalysisSunyoung S Lee, Dong Hyun Seo, Taek Chung, et al.
Molecular Cancer|March 27, 2024
RAF inhibitor re-challenge therapy in BRAF-aberrant pan-cancers: the RE-RAFFLE studyBlessie Elizabeth Nelson, Jason Roszik, Jibran Ahmed, et al.
Pancreas|March 14, 2014
Should combination chemotherapy serve as the backbone in clinical trials of advanced pancreatic cancer? A pooled analysis of phase II trials of gemcitabine-containing doublets plus bevacizumabKatherine Van Loon, Anne M Espinoza, David R Fogelman, et al.
Journal of Immunotherapy and Precision Oncology|January 16, 2025
Safety and Efficacy of Toripalimab in Patients with Cholangiocarcinoma: An Open-Label, Phase 1 StudyAung Naing, Amit Mahipal, Milind Javle, et al.
Pageof 35